Press Release


Printer Friendly Version View printer-friendly version
<< Back
Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Pipeline Programs at the 57th American Society of Hematology (ASH) Annual Meeting

Seven abstracts accepted including oral presentation on the Company’s controllable CAR-T product candidate BPX-401

HOUSTON--(BUSINESS WIRE)--Nov. 5, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that three abstracts on the Company’s lead product candidate, BPX-501, an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation, were accepted for poster presentation at the 57th American Society of Hematology (ASH) Annual Meeting. The Company will also highlight data in an oral presentation from a preclinical study with its BPX-401 controllable CAR-T (CIDeCAR™) product candidate for the treatment of B cell malignancies. The meeting will be held in Orlando, Florida December 5-8, 2015.

Investor/Analyst Luncheon

Bellicum will also host an investor and analyst luncheon on Monday, December 7, 2015 from 12:15 – 1:15 p.m. EST at the Hyatt Regency Orlando. Management and select key opinion leaders, including lead Principal Investigator, Professor Franco Locatelli, M.D., will review the BPX-501 Phase 1/2 clinical study data in pediatric patients with hematologic disorders. The luncheon will be webcast live and may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

Full List of ASH Presentations on Bellicum Programs

BPX-501:

Poster Presentation: “Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial”

  • Abstract Number: 1931
  • Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
  • Date: Saturday, December 5, 2015
  • Presentation Time: 5:30 PM - 7:30 PM EST

Poster Presentation: “Immune Reconstitution after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial”

  • Abstract Number: 3093
  • Session Name: 703. Adoptive Immunotherapy: Poster II
  • Date: Sunday, December 6, 2015
  • Presentation Time: 6:00 PM - 8:00 PM EST

Poster Presentation: “BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)”

  • Abstract Number: 4299
  • Session Name: 703. Adoptive Immunotherapy: Poster III
  • Date: Monday, December 7, 2015
  • Presentation Time: 6:00 PM - 8:00 PM EST

Additional data on more BPX-501 patients to be presented at ASH.

BPX-401:

Oral Presentation: “Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9”

  • Abstract Number: 851
  • Session Name: 703. Adoptive Immunotherapy: Preclinical Studies
  • Date: Monday, December 7, 2015
  • Presentation Time: 5:30 PM EST

BPX-601:

Poster Presentation: “Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells”

  • Abstract Number: 4295
  • Session Name: 703. Adoptive Immunotherapy: Poster III
  • Date: Monday, December 7, 2015
  • Presentation Time: 6:00 PM - 8:00 PM EST

Enhanced TCRs:

Poster Presentation: “Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma”

  • Abstract Number: 1886
  • Session Name: 703. Adoptive Immunotherapy: Poster I
  • Date: Saturday, December 5, 2015
  • Presentation Time: 5:30 PM - 7:30 PM EST

Bellicum Program Licensed from Leiden University Medical Center:

Poster Presentation: “T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies”

  • Abstract Number: 3002
  • Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
  • Date: Sunday, December 6, 2015
  • Presentation Time: 6:00 PM - 8:00 PM EST

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com